Methotrexate therapy in polymyositis

F. C. Arnett, J. C. Whelton, Thomas M. Zizic, M. B. Stevens

Research output: Contribution to journalArticle

Abstract

5 of 16 patients with polymyositis, whose disease could not be controlled with corticosteroids alone, received Methotrexate therapy. 4 had pure polymyositis while one had myositis associated with systemic sclerosis. As a group, they demonstrated, clinically and chemically, more severe muscle disease than those requiring steroids alone. 3 patients clearly responded to the drug, but toxicity was a significant limiting factor. The most serious complication, namely Methotrexate pneumonitis, observed in two patients receiving oral dosage, contributed to death in one. Methotrexate therapy, while a useful adjunct in the steroid refractory patient, is highly toxic, especially when given orally, and must be used with caution.

Original languageEnglish (US)
Pages (from-to)536-546
Number of pages11
JournalAnnals of the Rheumatic Diseases
Volume32
Issue number6
StatePublished - 1973

Fingerprint

Polymyositis
Methotrexate
Steroids
Poisons
Refractory materials
Myositis
Toxicity
Muscle
Systemic Scleroderma
Adrenal Cortex Hormones
Therapeutics
Drug-Related Side Effects and Adverse Reactions
Pneumonia
Pharmaceutical Preparations
Muscles

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Arnett, F. C., Whelton, J. C., Zizic, T. M., & Stevens, M. B. (1973). Methotrexate therapy in polymyositis. Annals of the Rheumatic Diseases, 32(6), 536-546.

Methotrexate therapy in polymyositis. / Arnett, F. C.; Whelton, J. C.; Zizic, Thomas M.; Stevens, M. B.

In: Annals of the Rheumatic Diseases, Vol. 32, No. 6, 1973, p. 536-546.

Research output: Contribution to journalArticle

Arnett, FC, Whelton, JC, Zizic, TM & Stevens, MB 1973, 'Methotrexate therapy in polymyositis', Annals of the Rheumatic Diseases, vol. 32, no. 6, pp. 536-546.
Arnett FC, Whelton JC, Zizic TM, Stevens MB. Methotrexate therapy in polymyositis. Annals of the Rheumatic Diseases. 1973;32(6):536-546.
Arnett, F. C. ; Whelton, J. C. ; Zizic, Thomas M. ; Stevens, M. B. / Methotrexate therapy in polymyositis. In: Annals of the Rheumatic Diseases. 1973 ; Vol. 32, No. 6. pp. 536-546.
@article{5665af0017854d97b56c15ef1456d62c,
title = "Methotrexate therapy in polymyositis",
abstract = "5 of 16 patients with polymyositis, whose disease could not be controlled with corticosteroids alone, received Methotrexate therapy. 4 had pure polymyositis while one had myositis associated with systemic sclerosis. As a group, they demonstrated, clinically and chemically, more severe muscle disease than those requiring steroids alone. 3 patients clearly responded to the drug, but toxicity was a significant limiting factor. The most serious complication, namely Methotrexate pneumonitis, observed in two patients receiving oral dosage, contributed to death in one. Methotrexate therapy, while a useful adjunct in the steroid refractory patient, is highly toxic, especially when given orally, and must be used with caution.",
author = "Arnett, {F. C.} and Whelton, {J. C.} and Zizic, {Thomas M.} and Stevens, {M. B.}",
year = "1973",
language = "English (US)",
volume = "32",
pages = "536--546",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - Methotrexate therapy in polymyositis

AU - Arnett, F. C.

AU - Whelton, J. C.

AU - Zizic, Thomas M.

AU - Stevens, M. B.

PY - 1973

Y1 - 1973

N2 - 5 of 16 patients with polymyositis, whose disease could not be controlled with corticosteroids alone, received Methotrexate therapy. 4 had pure polymyositis while one had myositis associated with systemic sclerosis. As a group, they demonstrated, clinically and chemically, more severe muscle disease than those requiring steroids alone. 3 patients clearly responded to the drug, but toxicity was a significant limiting factor. The most serious complication, namely Methotrexate pneumonitis, observed in two patients receiving oral dosage, contributed to death in one. Methotrexate therapy, while a useful adjunct in the steroid refractory patient, is highly toxic, especially when given orally, and must be used with caution.

AB - 5 of 16 patients with polymyositis, whose disease could not be controlled with corticosteroids alone, received Methotrexate therapy. 4 had pure polymyositis while one had myositis associated with systemic sclerosis. As a group, they demonstrated, clinically and chemically, more severe muscle disease than those requiring steroids alone. 3 patients clearly responded to the drug, but toxicity was a significant limiting factor. The most serious complication, namely Methotrexate pneumonitis, observed in two patients receiving oral dosage, contributed to death in one. Methotrexate therapy, while a useful adjunct in the steroid refractory patient, is highly toxic, especially when given orally, and must be used with caution.

UR - http://www.scopus.com/inward/record.url?scp=0015722941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015722941&partnerID=8YFLogxK

M3 - Article

C2 - 4760477

AN - SCOPUS:0015722941

VL - 32

SP - 536

EP - 546

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 6

ER -